MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR

CompletedOBSERVATIONAL
Enrollment

48

Participants

Timeline

Start Date

December 20, 2023

Primary Completion Date

May 13, 2024

Study Completion Date

May 13, 2024

Conditions
Ischemic Heart DiseaseCoronary Microvascular DiseaseAngina
Interventions
DEVICE

CardioFlux Magnetocardiography

The device is a magnetocardiography (MCG) scanner named CardioFlux, which is paired with a cloud processing software. CardioFlux devices are owned by Genetesis and are currently cleared for the acquisition, display, and analysis of magnetic fields generated by cardiac electrical activity (K182571, FDA clearance letter available for download online)

Trial Locations (4)

32608

University of Florida, Gainesville

44195

The Cleveland Clinic Foundation, Cleveland

45219

The Christ Hospital, Cincinnati

48236

Ascension St. John Hospital, Detroit

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Genetesis Inc.

INDUSTRY

NCT06139094 - MCG for Suspected INOCA Confirmed by Thermodilution-Derived CFR | Biotech Hunter | Biotech Hunter